Dose adjustment of carboplatin in patients on peritoneal dialysis

Medical Oncology

Volumn 31, Issue 5, 2014, Pages

  Guddati, Achuta K ^a   Joy, Parijat S ^b   Marak, Creticus P ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c Division of Pulmonary Medicine Department of Medicine Tahlequah City Hospital   (United States)

Author keywords

AUC; Carboplatin; Dose; Peritoneal dialysis

Indexed keywords

CARBOPLATIN;

AREA UNDER THE CURVE; ARTICLE; CALVERT EQUATION; DRUG CLEARANCE; DRUG INFUSION; HUMAN; MATHEMATICAL PHENOMENA; PERITONEAL DIALYSIS; PRIORITY JOURNAL;

EID: 84897347290     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0946-z     Document Type: Article

References (5)

1. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant. 2005;20(12):2587-93. doi:10.1093/ndt/gfi159. (Pubitemid 41672250)
2. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354(9173):93-9. (Pubitemid 29313142)
3. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748-56. (Pubitemid 19272848)
4. Guddati AK, Joy PS, Marak CP. Dose adjustment of carboplatin in patients on hemodialysis. Med Oncol. 2014;31(3):848. doi:10.1007/s12032-014-0848-0.
5. Heijns JB, van der BurgME, van Gelder T, FierenMW, de Bruijn P, van der Gaast A, et al. Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment. Cancer Chemother Pharmacol. 2008;62(5):841-7. doi:10.1007/s00280-007-0671-9.